Zeaxanthin Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Zeaxanthin dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Zeaxanthin.
Dosing Protocols
Beginner protocol — eye health maintenance and AMD risk reduction:
Step 1: Establish baseline and goals. For adults over 40 without diagnosed eye disease, the primary goal is AMD risk reduction and cataract prevention. For adults with intermediate AMD or advanced AMD in one eye, the goal is slowing progression with the full AREDS2 formulation. For young adults with heavy screen time, the goal is visual performance and fatigue reduction. Identify which category applies and proceed accordingly.
Step 2: Choose the delivery format. Most users benefit from a complete eye health formula containing AREDS2 ingredients in one or two capsules daily rather than assembling individual supplements. Quality brands include PreserVision AREDS2 (Bausch + Lomb, the original AREDS2 formulation used in the trial), MacuHealth, EyePromise, MacuShield (UK/EU), and Vitalux-S (Canada). All of these provide lutein 10 mg plus zeaxanthin 2 mg plus vitamin C plus vitamin E plus zinc plus copper at AREDS2-validated doses.
Step 3: Begin dosing at one capsule daily with the largest fat-containing meal of the day, typically dinner. AREDS2 dosing is 2 capsules daily (one with breakfast, one with dinner) for the full mineral and antioxidant load; some newer formulations consolidate to 1 capsule daily. Follow the specific product's directions.
Step 4: Build consistency over 12 weeks. Macular pigment optical density rises slowly — expect 8-12 weeks before any measurable change, 4-6 months before most of the accumulation occurs, and up to 12 months for full steady-state pigment deposition. Symptomatic changes in visual performance (glare tolerance, contrast sensitivity, screen-related fatigue) typically emerge at 8-16 weeks.
Step 5: Continue indefinitely. AMD risk reduction requires sustained supplementation; stopping leads to gradual loss of accumulated pigment over several months. Treat this like statin therapy or blood pressure medication — a long-term commitment, not a short cycle. Reassess every 12 months in the context of eye examinations and any changes in health status.
Intermediate protocol — zeaxanthin for specific clinical situations:
Step 1: For intermediate AMD or advanced AMD in one eye with the fellow eye at risk, use the full AREDS2 formulation as validated in the trial: lutein 10 mg + zeaxanthin 2 mg + vitamin C 500 mg + vitamin E 400 IU + zinc 25 mg (or 80 mg per original AREDS) + copper 2 mg. This is the evidence-based dose with a 26% progression risk reduction in the low-intake subgroup. Partner with an ophthalmologist for OCT monitoring, fundus photography, and pigment density tracking.
Step 2: For high-screen young adults with eyestrain, headache, or photophobia, use a targeted xanthophyll formula without the AREDS2 mineral package: lutein 12 mg + zeaxanthin 2-4 mg daily for 6 months, following Stringham's B.L.U.E. protocol. MacuHealth contains 10 mg lutein + 2 mg zeaxanthin + 10 mg meso-zeaxanthin as a premium option. Expect improvements in sleep quality, eyestrain, and glare tolerance at 12-16 weeks.
Step 3: For cataract prevention in mid-life (age 50-65), the AREDS2 formulation plus dietary emphasis on xanthophyll-rich foods (kale, spinach, orange bell peppers, eggs from pastured hens) is the evidence-based approach. Add astaxanthin 4-8 mg daily for systemic antioxidant coverage. No single trial has isolated cataract prevention effects, but epidemiologic evidence across multiple cohorts supports the combined approach.
Step 4: For post-cataract surgery patients, continuing the AREDS2 formulation is evidence-based because cataract surgery removes the crystalline lens — which normally filters some blue light before it reaches the retina — and therefore increases blue light exposure at the macula. A pseudophakic eye benefits from maximal macular pigment to compensate for the lost lens filtering. Continue indefinitely.
Step 5: For diabetic retinopathy or pre-retinopathy, add alpha lipoic acid 300-600 mg daily and optimize glycemic control aggressively. The AREDS2 formulation provides general retinal protection; diabetic retinopathy has additional microvascular and inflammatory pathology that benefits from broader antioxidant coverage.
Step 6: For light-sensitive conditions (retinitis pigmentosa, rod-cone dystrophies, vitamin A-sensitive dystrophies), xanthophyll supplementation may provide protective benefit through blue light filtration and PUFA membrane stabilization. This is less evidence-based than AMD but mechanistically supported; partner with a retinal specialist.
Step 7: For drivers, pilots, and others with high-glare occupational visual demand, Stringham 2012 showed that zeaxanthin plus lutein supplementation improved photostress recovery (the time required to regain visual function after bright light exposure) by 20-40%. This may have practical value for occupational visual performance.
Advanced protocol — specialist applications:
Step 1: Macular pigment optical density (MPOD) measurement — request MPOD measurement at baseline through a vision specialist using heterochromatic flicker photometry or dual-wavelength autofluorescence. Baseline MPOD varies from 0.1 (very low) to 1.2 (very high) among healthy adults. Target MPOD above 0.6-0.8 for robust macular protection. Remeasure at 6 and 12 months to track pigment accumulation response to supplementation. People with very low baseline MPOD are expected to benefit most from supplementation; people with naturally high dietary xanthophyll intake and MPOD above 1.0 may plateau early.
Step 2: Meso-zeaxanthin supplementation — standard zeaxanthin supplements contain (3R,3'R)-zeaxanthin, the dietary form. Meso-zeaxanthin (3R,3'S) is formed in the retina from lutein substrate but dietary meso-zeaxanthin is essentially zero. Some premium formulations (Lutemax 2020, MacuHealth, some Industrial Organica products) include meso-zeaxanthin 10 mg to accelerate central foveal pigment formation. Trials by Nolan 2014, Loughman 2012, and Bone 2007 suggest meso-zeaxanthin supplementation increases central foveal MPOD faster than lutein alone. For patients with established AMD, advanced MPOD deficit, or central foveal thinning on OCT, meso-zeaxanthin supplementation may be valuable.
Step 3: High-dose protocols — some specialists use lutein 20-40 mg plus zeaxanthin 4-8 mg daily in advanced AMD with rapidly progressing geographic atrophy, drawing on the Zeaxanthin and Visual Function Study 8 mg daily protocol and clinical experience. These doses are well above AREDS2 but within the safety envelope established by toxicology studies. Use only under specialist supervision with MPOD and OCT monitoring.
Step 4: Low-carotenoid-diet patients — vegetarians, vegans, and others with very high dietary xanthophyll intake from kale, spinach, and broccoli often have high baseline MPOD and may show less incremental benefit from supplementation. Measure MPOD first. Patients with low dietary xanthophyll intake (Western fast-food pattern, low vegetable consumption) show the largest MPOD response to supplementation and the largest AMD risk reduction in AREDS2 subgroup analysis.
Step 5: Genetic considerations — the Y402H polymorphism in complement factor H (CFH) and the A69S polymorphism in ARMS2 are major AMD risk alleles. Genetic testing is increasingly available and may inform risk stratification. AREDS2 subgroup analyses by CFH genotype were mixed; the utility of genetic testing for guiding supplementation dose is not established but may become relevant in personalized medicine contexts.
Step 6: Combined carotenoid serum testing — some laboratories offer comprehensive carotenoid panels measuring zeaxanthin, lutein, beta-carotene, alpha-carotene, lycopene, and beta-cryptoxanthin. These are useful for tracking supplementation response in research contexts and for identifying patients with severe absorption deficits. Not routinely needed for clinical practice.
Step 7: Integration with anti-VEGF therapy — patients receiving intravitreal anti-VEGF injections for neovascular AMD (aflibercept, ranibizumab, bevacizumab) can and should continue AREDS2 supplementation. The interventions address different disease processes (neovascular wet AMD versus progression of dry AMD to advanced stages) and there are no known interactions.
Step 8: Post-photocoagulation or photodynamic therapy — patients recovering from laser treatments benefit from continued xanthophyll supplementation to support remaining photoreceptor function and minimize additional oxidative damage in surrounding tissue.
Step 9: Pediatric light-sensitive dystrophy — specific inherited retinal conditions (Stargardt disease, cone dystrophies, X-linked retinoschisis) may benefit from xanthophyll supplementation to protect remaining photoreceptor function. This is strictly a specialist retinal dystrophy clinic decision based on case-by-case clinical reasoning, not a general pediatric recommendation.
Step 10: Long-term persistence — retinal xanthophyll concentrations fall gradually after supplementation stops, with half-life on the order of 60-120 days. Patients who stop supplementation retain benefit for several months but lose it fully within a year. Compliance is therefore critical; discuss long-term adherence explicitly at each visit.
Commonly Stacked With
Zeaxanthin stacks naturally with several evidence-based eye health compounds and with broader antioxidant systems. The two most important co-supplements are lutein and meso-zeaxanthin because these three xanthophylls together constitute the macular pigment. Standard AREDS2-style supplementation uses lutein 10 mg plus zeaxanthin 2 mg in a 5:1 ratio reflecting typical dietary ratios; some premium formulations add meso-zeaxanthin 10 mg to support central foveal pigment where meso-zeaxanthin dominates. Lutemax 2020 is a branded ingredient that combines all three in a single capsule. Taking zeaxanthin without lutein is rarely appropriate; the combination is what has been studied and what correlates with clinical outcomes.
Vitamin C 500 mg daily is part of the AREDS and AREDS2 core formulation. Vitamin C regenerates oxidized vitamin E back to the reduced form, supports collagen synthesis in the retina and lens, and contributes to aqueous humor antioxidant capacity. Vitamin E 400 IU daily (historically 400 IU of dl-alpha-tocopherol in AREDS, newer formulations prefer mixed tocopherols with gamma-tocopherol) works alongside vitamin C and xanthophylls to protect polyunsaturated fatty acids in photoreceptor membranes from lipid peroxidation.
Zinc 25-80 mg daily (AREDS used 80 mg; AREDS2 tested lower 25 mg finding similar efficacy with better tolerability) supports retinal enzymes including superoxide dismutase and multiple retinol-related dehydrogenases. Copper 2 mg daily must accompany zinc at this dose to prevent copper-deficiency anemia from chronic zinc supplementation. The AREDS2 mineral package is not optional — leaving zinc out gives up a significant fraction of the trial-demonstrated benefit.
Omega-3 fatty acids, particularly DHA at 350-1000 mg daily, are structurally enriched in photoreceptor outer segment membranes where they constitute up to 60% of total phospholipid fatty acid content. DHA membranes benefit from xanthophyll antioxidant protection. AREDS2 tested omega-3 and did not find independent benefit on AMD progression, but DHA has its own benefits for dry eye, retinal function, and systemic cardiovascular health that support combination supplementation.
Astaxanthin 4-12 mg daily complements zeaxanthin by providing systemic antioxidant coverage and, debatably, additional retinal antioxidant support. Astaxanthin and zeaxanthin share the xanthophyll family and transmembrane orientation but astaxanthin does not concentrate in the macula in meaningful amounts — it provides peripheral retinal and general tissue antioxidant protection rather than macular pigment contribution.
Bilberry extract 160-320 mg daily standardized to 25% anthocyanosides is traditionally used for retinal microcirculation and night vision. The evidence base is smaller than for AREDS2 but the mechanism (rhodopsin regeneration support, capillary integrity) is complementary rather than overlapping with xanthophyll pigment filtration.
Alpha lipoic acid 200-600 mg daily supports retinal antioxidant regeneration through thioredoxin and glutathione systems; its relevance is greatest in diabetic retinopathy where oxidative-neuropathic mechanisms dominate. CoQ10 100-200 mg daily supports retinal mitochondrial function particularly relevant to geographic atrophy and photoreceptor metabolic stress.
Vitamin D3 1000-5000 IU daily has emerging associations with AMD risk reduction and supports general systemic immune and inflammatory homeostasis relevant to macular health. Resveratrol and pterostilbene through Nrf2 and SIRT1 pathways may amplify the antioxidant response activated by xanthophylls, though direct trial evidence for eye health is limited.
Dietary enhancement of zeaxanthin bioavailability is straightforward: consume with a fat-containing meal. Olive oil, avocado, nuts, fatty fish, or eggs all provide the lipid matrix needed for efficient chylomicron incorporation. The effect is substantial — taking zeaxanthin with a fat-free meal can reduce absorption by 50-80%.
Stacks to avoid or time-separate include high-dose beta-carotene which competes with zeaxanthin at intestinal absorption and which carries smoker lung cancer risk that zeaxanthin specifically replaces; simultaneous high-dose single carotenoid loading; and coadministration with cholestyramine or orlistat which reduce lipophilic absorption (separate by 2-4 hours).
The canonical eye health stack for bodyhackguide readers is: AREDS2 formulation (lutein 10 mg + zeaxanthin 2 mg + vitamin C 500 mg + vitamin E 400 IU + zinc 25 mg + copper 2 mg) + omega-3 with DHA 500-1000 mg + optional astaxanthin 4 mg for systemic antioxidant coverage + optional bilberry extract for microcirculation + vitamin D3 at replete levels. This stack is the evidence-based consensus for AMD prevention, cataract risk reduction, and visual performance optimization.
For visual performance in high-screen young adults, Stringham's B.L.U.E. protocol of lutein 12 mg plus zeaxanthin 2 mg for 6 months is sufficient; the AREDS2 mineral package is unnecessary in healthy young eyes without AMD risk.
Timing: zeaxanthin has a long half-life (weeks in retinal tissue) so strict daily dosing is less critical than for shorter-half-life molecules. Missing a day or two is inconsequential. Taking the dose at the same meal daily (usually breakfast or lunch with a fat-containing meal) is convenient and ensures consistent absorption.
Side Effects & Safety
Contraindications
Contraindications for zeaxanthin supplementation are few and largely theoretical rather than clinically demonstrated. Absolute contraindications: None clinically established. Zeaxanthin at typical supplementation doses of 1-12 mg daily has not shown serious adverse effects in any large trial or surveillance study. Relative contraindications and caution situations: Known hypersensitivity to marigold (Tagetes erecta) extract or to specific supplement excipients. Marigold-derived zeaxanthin is the most common commercial source, and people with documented marigold allergy should either avoid it or use a fermentation-sourced product. Active carotenodermia from dietary or supplement excess. Patients already showing yellow-orange palm and sole pigmentation from high beta-carotene or xanthophyll intake should reduce total carotenoid load rather than add more zeaxanthin; carotenodermia is cosmetic but suggests cumulative intake above useful physiologic levels. Severe fat malabsorption (biliary obstruction, advanced pancreatic insufficiency, extensive small bowel resection, steatorrhea syndromes) — oral zeaxanthin absorption will be minimal and supplementation is unlikely to achieve meaningful serum or tissue levels. Address underlying malabsorption before expecting supplement benefit. Cholestyramine, colestipol, or orlistat therapy — these medications reduce fat absorption and secondarily reduce zeaxanthin absorption. Separate doses by at least 2-4 hours; may need higher zeaxanthin dose to achieve usual serum levels. Pregnancy: Dietary zeaxanthin through food is unambiguously safe. Supplementation at AREDS2 dose of 2 mg daily is considered low-risk; high-dose zeaxanthin protocols (4-8 mg daily) have not been studied in pregnancy and should be avoided without specific obstetric indication. Pediatric use: Not indicated for healthy children. Dietary intake through food is adequate. Specific retinal dystrophy diagnoses may warrant pediatric supplementation under specialist care. Patients preferring beta-carotene formulations: Zeaxanthin is not a provitamin A carotenoid, and patients with clinical vitamin A deficiency should not rely on zeaxanthin supplementation to correct their deficiency. Use a provitamin A carotenoid (beta-carotene, alpha-carotene, beta-cryptoxanthin) or preformed vitamin A (retinyl palmitate) for vitamin A status. Patients on multiple carotenoid supplements: High simultaneous intake of multiple carotenoids can produce intestinal absorption competition. Stagger doses through the day or rely on a complete carotenoid-diverse formulation rather than stacking individual high-dose products. Liver disease: No specific hepatotoxicity with zeaxanthin, but patients with severe hepatic impairment may have reduced bile acid secretion affecting absorption and may have altered lipid handling. Use cautiously and monitor. Active cancer or cancer survivorship: Zeaxanthin has not been associated with cancer risk and does not share the beta-carotene smoker lung cancer signal. Epidemiologic data do not suggest cancer-promoting activity; however, in the absence of large interventional trials specifically in cancer populations, caution and oncologist consultation are reasonable. Smoking: Zeaxanthin is specifically the preferred carotenoid for smokers and former smokers because it replaces beta-carotene in AREDS2 and does not share the lung cancer signal. This is not a contraindication — it is actually an indication over beta-carotene. Genetic carotenoid conversion variants: BCO1 (beta-carotene 15,15'-oxygenase 1) polymorphisms affecting conversion of beta-carotene to retinal are irrelevant for zeaxanthin, which is not a BCO1 substrate. Autoimmune eye disease (uveitis, birdshot chorioretinopathy, sympathetic ophthalmia): Zeaxanthin supplementation is not contraindicated but also has no specific evidence base in these conditions. Use standard AREDS2-style approach if concurrent AMD risk exists; primary management should address the autoimmune process. Allergic reactions: Rare; typically limited to marigold hypersensitivity. Stop if any unexplained rash, respiratory symptom, or gastrointestinal distress develops. Overall, zeaxanthin supplementation at the AREDS2 dose is one of the lowest-risk interventions in nutritional medicine. The risk-benefit profile strongly favors supplementation for adults with AMD risk, high screen time, or aging-related visual decline. The main practical consideration is ensuring appropriate co-supplementation with lutein (and optionally meso-zeaxanthin) rather than standalone zeaxanthin use.
Additional Notes
Standard AREDS2 dose: Lutein 10 mg plus zeaxanthin 2 mg daily taken with a fat-containing meal, as part of the complete AREDS2 formula (vitamin C 500 mg, vitamin E 400 IU, zinc 25-80 mg, copper 2 mg). This is the evidence-based validated dose with established 26% AMD progression risk reduction in the low-intake subgroup.
Higher-dose zeaxanthin protocols in research: The Zeaxanthin and Visual Function Study used 8 mg zeaxanthin daily. Some specialists use 4-8 mg for advanced AMD or rapidly progressing cases. Safety margin exists up to 20-30 mg daily based on short-term tolerability studies, but benefit beyond 2-4 mg is not established in randomized trials.
Young adult visual performance dose: Lutein 12 mg plus zeaxanthin 2-4 mg daily per Stringham's B.L.U.E. protocol. Without the AREDS2 mineral package unless specific nutritional deficiency exists.
Meso-zeaxanthin inclusion: Premium formulations (Lutemax 2020, MacuHealth) add meso-zeaxanthin 10 mg. Mechanism rationale favors inclusion for central foveal pigment formation, particularly in older patients with advanced pigment deficit or established AMD.
Timing: Take with breakfast or dinner — whichever meal reliably contains fat. Olive oil, avocado, butter, eggs, fatty fish, nuts, or oily dressing are all sufficient. Fat-free meals dramatically reduce absorption (up to 80% loss).
Duration: Long-term indefinite use is appropriate for AMD prevention and cataract risk reduction. Short cycles (weeks to months) are inadequate because MPOD accumulation takes 6-12 months. Treat like a cardiovascular preventive therapy — continuous daily use is the expected pattern.
Pediatric use: Not recommended without a specific retinal dystrophy diagnosis. Dietary xanthophyll intake through food is sufficient for healthy children.
Pregnancy: Dietary intake through food is unambiguously safe. Supplementation at 2 mg zeaxanthin daily is considered low-risk but should be discussed with an obstetrician. Avoid high-dose zeaxanthin protocols during pregnancy.
Lactation: Zeaxanthin concentrates in breast milk proportional to maternal status. Standard supplementation doses are acceptable.
Geriatric use: No dose adjustment for age. Older adults with absorption issues (atrophic gastritis, pancreatic insufficiency) may need higher doses or attention to fat intake.
Renal and hepatic impairment: No dose adjustment required. Zeaxanthin is excreted primarily through biliary-fecal pathways and has negligible renal handling.
Brand notes: PreserVision AREDS2 is the original trial formulation from Bausch + Lomb. MacuHealth and EyePromise are premium brands including meso-zeaxanthin. Most pharmacy-brand generic AREDS2 formulations are acceptable quality. OPTISHARP (DSM), Lutemax 2020 (OmniActive), and EZEyes are high-quality ingredient brands used in various commercial products.
Common mistakes: (1) Taking zeaxanthin without lutein — the combination is what is studied, not zeaxanthin alone. (2) Taking with fat-free meals — absorption drops substantially. (3) Short cycles — MPOD accumulation takes months, not weeks. (4) Expecting immediate symptomatic change — visual improvements emerge at 8-16 weeks in young adults and 4-6 months in older AMD patients. (5) Discontinuing after symptomatic benefit — benefit requires continuous supplementation. (6) Using beta-carotene-containing formulations in smokers — use lutein plus zeaxanthin instead per AREDS2 substitution.
Frequently Asked Questions
What is the recommended Zeaxanthin dosage?
Dosage for Zeaxanthin varies by protocol. Consult a qualified healthcare provider.
How often should I take Zeaxanthin?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Zeaxanthin need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Zeaxanthin side effects?
Zeaxanthin has one of the cleanest side effect profiles of any nutritional supplement, with no serious adverse events reported in any of the large-scale trials including AREDS2 (4,203 participants for 5 years), and no signal of increased mortality, cancer, or cardiovascular events. The single reliably reported effect at high intakes is carotenodermia — a harmless yellow-orange pigmentation of the skin, particularly visible on the palms, soles of the feet, and nasolabial folds. Carotenodermia is not jaundice; the sclera of the eyes remains white because carotenoids do not accumulate in ocular surface tissues the way bilirubin does. Carotenodermia occurs at very high sustained intakes (typically above 20-30 mg daily of total carotenoids from all sources including food) and resolves completely within 2-6 weeks of reducing intake. It is cosmetic only and has no physiologic consequence. Gastrointestinal tolerance is excellent. Occasional mild gastrointestinal symptoms — loose stools, bloating, nausea — have been reported but at rates not different from placebo in controlled trials. Taking zeaxanthin with food, particularly fat-containing food, eliminates the rare gastrointestinal complaint and also maximizes absorption. The AREDS2 trial specifically addressed the smoker safety concern that emerged from the CARET and ATBC trials of beta-carotene. In AREDS2, former smokers receiving lutein plus zeaxanthin did not show an increase in lung cancer incidence, and the substitution of lutein plus zeaxanthin for beta-carotene was made precisely because of the beta-carotene safety signal in smokers. Current and former smokers should use lutein plus zeaxanthin rather than beta-carotene-containing formulations. This is a favorable distinction for zeaxanthin compared to its provitamin A cousin. Drug interactions are minimal. Zeaxanthin does not meaningfully affect cytochrome P450 activity, does not affect warfarin or other anticoagulants, and does not produce clinically relevant changes in absorption of concomitant medications. The one theoretical interaction is with lipid-binding medications (cholestyramine, colestipol, orlistat) that reduce dietary fat absorption and consequently reduce carotenoid absorption; separating doses by 2-4 hours addresses this. Pregnancy and lactation data are limited. Zeaxanthin is naturally present in breast milk at concentrations reflecting maternal dietary and supplementation status, and epidemiologic data on dietary zeaxanthin intake during pregnancy show no harm, but controlled supplementation trials during pregnancy have not been conducted. The practical recommendation is that dietary zeaxanthin through foods (eggs, goji berries, orange bell peppers, corn) is unambiguously safe during pregnancy, and supplemental zeaxanthin at the AREDS2 dose of 2 mg daily is considered low-risk but should be discussed with an obstetrician. Pediatric data are similarly limited. Healthy children receive dietary zeaxanthin through foods, and no supplementation trials in children have been conducted. Supplementation in children without a specific medical indication is not supported by evidence. Carotenoid-carotenoid competition at intestinal absorption is a mild consideration. High doses of zeaxanthin taken simultaneously with high doses of beta-carotene or lycopene may reduce absorption of the other carotenoids due to competition at the intestinal lipid micellar incorporation step. In practice, dietary diversity and staggered dosing minimize this effect, and it is unlikely to produce clinically meaningful deficiency. Liver function is not affected by zeaxanthin supplementation at any tested dose. Unlike vitamin A (retinol, retinyl palmitate), zeaxanthin cannot cause hypervitaminosis A because it is not enzymatically cleaved to retinal in any meaningful amount — zeaxanthin is a non-provitamin A carotenoid lacking the unsubstituted beta-ionone ring structure needed for cleavage to retinal by BCO1 (beta-carotene 15,15'-oxygenase 1). There are isolated case reports of retinal crystalline deposits (canthaxanthin retinopathy) associated with very high doses of canthaxanthin, a related carotenoid once used as a tanning supplement. Zeaxanthin has not been associated with retinopathy at any tested dose, and the specific structural features of canthaxanthin (keto groups on both rings) are not present in zeaxanthin. Individual idiosyncratic reactions are rare but have been reported: mild rash, headache, or gastrointestinal upset that resolves with discontinuation. These are not more frequent than background rates in placebo arms and should be managed by stopping the supplement if any individual experiences an unexpected symptom.
Where can I buy Zeaxanthin?
Visit our vendor directory to find trusted sources for Zeaxanthin.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
